Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Physician Training Options Remain Limited After Initial Launch

Executive Summary

FDA encourages physicians to take advantage of an educational program funded by sponsors of the analgesics as part of the REMS for extended-release opioid products, but only three programs were identified by the March 1 launch date, with Boston University taking the lead.

Advertisement

Related Content

Opioid Indication Change Could Draw Legal Challenge From Physicians Group Seeking More Restrictions
REMS Education Paradox: How Can Sponsors Create Independent CME?
Opioid Training Syllabus Increases Emphasis On Patient Monitoring In Final REMS Blueprint
Opioid Prescriber Education Mandate Could Be Added To User Fee Bill
FDA's CME Expectations For Opioid Prescribers Keep Sponsors At A Distance

Topics

Advertisement
UsernamePublicRestriction

Register

PS055197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel